4//SEC Filing
HANSEN JOHN DAVID 4
Accession 0001415889-17-001297
CIK 0001109196other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 6:02 AM ET
Size
11.2 KB
Accession
0001415889-17-001297
Insider Transaction Report
Form 4
HANSEN JOHN DAVID
DirectorPresident and CEO
Transactions
- Sale
Class B Warrant
2017-05-19−3,119→ 0 totalExercise: $6.29→ Common Stock (3,119 underlying) - Purchase
Common Stock
2017-05-19$1.75/sh+4,286$7,501→ 65,759 total - Purchase
Common Stock
2017-05-19+4,842→ 70,601 total - Sale
Class A Warrant
2017-05-19−3,119→ 0 totalExercise: $5.55→ Common Stock (3,119 underlying)
Footnotes (3)
- [F1]These shares were received in exchange for making an investment under the terms of the Company's May 2017 public offering equal to 50% of investment made in the Company's August 2016 public offering, and for the cancellation of (i) warrants to purchase 3,119 shares of the Company's common stock at a price per share of $5.55 issued to the Reporting Person on August 17, 2016 and (ii) warrants to purchase 3,119 shares of the Company's common stock at a price per share of $6.29 issued to the Reporting Person on August 17, 2016.
- [F2]Warrant is immediately exercisable and expires on August 17, 2019.
- [F3]These warrants were cancelled and exchanged for the right to receive 4,842 shares of common stock of the Company.
Documents
Issuer
MABVAX THERAPEUTICS HOLDINGS, INC.
CIK 0001109196
Entity typeother
Related Parties
1- filerCIK 0001186123
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 6:02 AM ET
- Size
- 11.2 KB